ADVANCED INTERVENTIONAL REGENERATIVE MEDICINE
The cells. The method.
The team behind your care.
At Stem Cell Mexico, we bring together personalized evaluation, carefully selected biological therapies and targeted application through the Stem Cell Mexico System, under the medical direction of Dr. César Amescua.
Your care connects medical expertise, diagnostics, treatment planning and patient coordination, so you can understand your options and move forward with a clear plan.
UNDERSTAND THE DIFFERENCE
A system of care.
More than a single treatment.
The choice of cells matters. So do patient selection, handling, delivery, the team performing the procedure and what happens afterward.
Step 01: Evaluate the person
We review your diagnosis, symptoms, medical history, medications and relevant imaging to understand whether our approach is appropriate for you.
Step 02: Design the approach
Your physician selects the biological product, delivery route, anatomical targets and planned dose around your individual case.
Step 03: Coordinate the team
We coordinate the treating physician, radiology and procedural support according to your treatment needs.
Step 04: Follow the progress
We establish realistic goals, explain your aftercare and follow your progress over time.
EXPERIENCE GUIDES THE METHOD
Medical leadership.
A coordinated team.
Dr. César Amescua leads our clinical approach and the guidelines behind the Stem Cell Mexico System. His interventional and pain-medicine experience helps shape your treatment plan alongside the evidence relevant to your condition.
Your care may involve a radiologist and other specialists for image interpretation and guided application. We explain who will be involved and how each professional contributes to your care.
MedicalMex coordinates records, scheduling and cross-border logistics. Licensed physicians remain responsible for medical decisions.
PRECISION IN THE APPLICATION
The target is chosen
for your anatomy.
The area that hurts, the structure shown on an image and the appropriate application site are not always the same.
Review the condition and imaging
We begin with your clinical assessment and relevant imaging to understand the structures involved and whether targeted treatment is appropriate.
Select the anatomical target
We select specific areas for application based on your anatomy and diagnosis. Under Dr. Amescua’s approach, that may mean targeting an area adjacent to the damaged structure rather than injecting directly into it.
Use the appropriate imaging method
We use imaging guidance appropriate to the procedure, such as ultrasound or fluoroscopy, to visualize anatomy and guide placement. Precise placement supports the procedure; your response also depends on your condition and the therapy used.
YOUR TREATMENT, EXPLAINED
“Where will you apply the treatment, and why there?”
Before treatment, we explain where we propose to apply the therapy, why that location was selected and what the procedure involves, including its risks.
Our aim is to minimize unnecessary tissue trauma through an individualized interventional approach. Your physician determines the location and technique for your medical plan.
CELL SOURCE & CLINICAL INTENT
Different biological options.
A reason for each choice.
We select biological therapies according to your diagnosis, clinical goals and the evidence available. Each source has different characteristics, and suitability begins with your medical evaluation.
DENTAL PULP–DERIVED CELLS
A neurological research rationale.
We consider dental pulp–derived cells for selected neurological and neurodegenerative cases. Their neural-crest origins and the nerve-supporting factors studied in laboratory research help explain the interest in this source.
This research provides a biological rationale, but it does not establish that treatment can replace lost neurons or reverse a neurological condition. Your evaluation considers the human evidence and limitations relevant to your diagnosis.
WHARTON’S JELLY–DERIVED CELLS
An option considered for musculoskeletal care.
We use cells derived from Wharton’s jelly, the connective tissue of the umbilical cord, in selected musculoskeletal and wellness protocols. Your physician connects the choice of cell source to your specific goals and proposed treatment.
Wharton’s jelly is different from umbilical cord blood. Your evaluation focuses on the proposed product and meaningful goals for your care, rather than treating every cord-derived product as interchangeable.
CELL-DERIVED EXTRACELLULAR VESICLES
A limited role in selected cartilage cases.
We consider exosomes in selected cases of limited cartilage damage. These small cell-derived vesicles are different from living stem cells and require their own product characterization and quality controls.
Evidence for cartilage applications is still developing, and clinical benefit remains uncertain. We do not promise cartilage regrowth; suitability depends on the extent of damage, your symptoms and the available treatment options.
QUALITY YOU CAN UNDERSTAND
What goes into
your planned dose?
Understanding your planned dose means looking at the cell count, viability and handling together. We explain these terms so you can understand what your treatment proposal means.
OUR VIABILITY TARGET
97%+
A quality target.
Not a success rate.
Our viability target is 97% or above. Viability describes the proportion of cells measured as living at a particular testing point. It is a quality measurement, not a prediction of your treatment result or a guarantee of survival after administration.
How does cell preparation affect my treatment?
Cell source, culture history and handling are separate parts of product quality. Labels such as “first-generation” do not have one universal passage definition and cannot, by themselves, establish effectiveness. Your treatment is evaluated in the context of the specific product and your condition.
Are we discussing total cells or viable cells?
Total cells include all cells counted; viable cells are those measured as living. The distinction matters when interpreting a proposed dose, and the timing of the measurement matters too.
What is the additional cell-count margin?
Our dose planning includes an allowance for expected handling losses within the prescribed protocol. This margin supports planning for the intended viable-cell dose; it does not replace quality checks or guarantee cell survival after treatment.
Can additional cells compensate for a quality problem?
No. A cell-count margin addresses anticipated handling losses, not contamination or another failed quality requirement. Dose and product quality are separate considerations.
Does higher viability mean greater effectiveness?
No. Viability measures whether cells are alive according to the assay used. Identity, purity, contamination testing, potency, handling, dose, route and clinical evidence answer different questions.
RECOVERY WITH REALISTIC EXPECTATIONS
Less procedural trauma.
A clear plan for afterward.
The approach aims to minimize unnecessary tissue trauma. Recovery depends on the procedure, treated area, sedation, baseline mobility and the individual patient.
Before you leave
We check how you are doing and explain your mobility, transport and observation instructions. Depending on the procedure and medical clearance, some patients may walk shortly afterward.
During the first few days
Your aftercare guidance covers expected soreness, activity limits and any assistance you may need. Returning to everyday activities and returning to strenuous exercise are different milestones.
During follow-up
We follow your symptoms, function and agreed clinical measures over time. Being able to walk soon after a procedure describes recovery from the procedure; improvement in the underlying condition is assessed separately.
ANSWERS FOR YOUR DECISION
Technical answers.
Practical meaning.
You deserve clear answers before choosing care. Here we explain the technical terms that can help you understand your options and discuss your individual plan with our medical team.
We connect the science to what matters for you: suitability, product quality, delivery, risks and realistic goals.
Are the cells mine or donor-derived?
Autologous means cells collected from your own body; allogeneic means cells from a donor. The dental pulp and umbilical cord sources discussed on this page describe tissue origin. Your individual proposal identifies the product selected for your care.
Are the cells fresh or cryopreserved?
These terms describe how a product is prepared and stored. Cryopreserved cells are frozen and then thawed before use. Handling and timing matter, and a viability measurement taken before freezing does not automatically describe viability at administration.
What tests establish product quality?
Product quality involves several distinct checks, including identity, cell count, viability and contamination testing. No single percentage tells the whole story. The relevant tests and release criteria depend on the particular biological product.
Is a larger dose always better?
No. We individualize the planned dose around the product, delivery route and your clinical circumstances. More cells alone do not establish better results, and repeated treatment requires its own medical evaluation.
Will the cells reach or remain in the target tissue?
Targeted placement describes where the therapy is delivered. It does not guarantee that cells remain there, survive long term or produce a clinical benefit. Your physician explains the purpose and limitations of the proposed route.
Does image guidance make the treatment proven?
Imaging helps us visualize anatomy and guide placement. The evidence for the therapy itself is a separate consideration, which we assess in relation to your diagnosis.
What are my risks and alternatives?
Your medical evaluation considers your health history, the proposed product and the procedure. We discuss relevant risks, uncertainties and alternatives before you decide, along with the aftercare guidance for your plan.
How are outcomes measured?
We focus on changes in your symptoms, function and relevant clinical measures over time. Patient stories can help you understand the care experience, but an individual review cannot predict your own result.
Is this the same as participating in a clinical trial?
No. Receiving treatment and enrolling in a clinical trial are different. A clinical trial has a defined research protocol, oversight and a separate consent process. Treatment alone does not mean you are participating in a study.
What does regulatory authorization cover?
Facility licensing, laboratory credentials and authorization for a particular treatment serve different purposes. One does not automatically establish the others or prove effectiveness. Care in Mexico should not be interpreted as FDA approval of a product or use.
What is included in my quote?
Your personalized proposal outlines the recommended care and pricing. Vania helps you review the treatment, testing, facility services, travel coordination and follow-up included in your package, together with any separate costs.
EXPLORE THE EVIDENCE
Understand the science behind your options.
Explore independent research and patient resources related to the cell sources, handling and therapies discussed here. These sources provide context; they do not establish the effectiveness of every Stem Cell Mexico protocol.
